Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 113-120 , March 2006

Hepatitis C infection and diabetes

  • Hiroshi Noto
    • ,
  • Philip Raskin

      Affiliations

    • Corresponding Author InformationCorresponding author. Division of Endocrinology and Metabolism, Department of Internal Medicine, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390-8858, USA. Tel.: +1 214 648 2017; fax: +1 214 648 4854.

Received 22 November 2005 ,Accepted 4 January 2006.

References 

  1. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Koff JM, Holtzmuller KC, et al. Impact of diabetes and hepatitis after kidney transplantation on patients who are affected by hepatitis C virus. Journal of the American Society of Nephrology. 2004;15:3166–3174
  2. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. Journal of Hepatology. 1994;21:1135–1139
  3. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: A mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38:1384–1392
  4. Bahtiyar G, Shin JJ, Aytaman A, Sowers JR, McFarlane SI. Association of diabetes and hepatitis C infection: Epidemiologic evidence and pathophysiologic insights. Current Diabetes Reports. 2004;4:194–198
  5. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology. 2000;32:87–90
  6. Bloom RD, Rao V, Weng F, Grossman RA, Cohen D, Mange KC. Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus. Journal of the American Society of Nephrology. 2002;13:1374–1380
  7. Bloomgarden ZT. Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease. Diabetes Care. 2005;28:1518–1523
  8. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care. 2005;28:2061–2063
  9. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore). 2000;79:47–56
  10. Campbell S, McLaren EH, Danesh BJ. Rapidly reversible increase in insulin requirement with interferon. British Medical Journal. 1996;313:92
  11. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;30:1059–1063
  12. Chedin P, Cahen-Varsaux J, Boyer N. Non-insulin-dependent diabetes mellitus developing during interferon-alpha therapy for chronic hepatitis C. Annals of Internal Medicine. 1996;125:521
  13. Cheung AT, Wang J, Ree D, Kolls JK, Bryer-Ash M. Tumor necrosis factor-alpha induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes. 2000;49:810–819
  14. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002;35:373–379
  15. Chou CJ, Haluzik M, Gregory C, Dietz KR, Vinson C, Gavrilova O, et al. WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice. Journal of Biological Chemistry. 2002;277:24484–24489
  16. de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22:756–761
  17. di Cesare E, Previti M, Russo F, Brancatelli S, Ingemi MC, Scoglio R, et al. Interferon-alpha therapy may induce insulin autoantibody development in patients with chronic viral hepatitis. Digestive Diseases and Sciences. 1996;41:1672–1677
  18. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: A case-control study among United States Veterans. American Journal of Gastroenterology. 2001;96:2462–2467
  19. Elsammak M, Refai W, Elsawaf A, Abdel-Fattah I, Abd Elatti E, Ghazal A. Elevated serum tumor necrosis factor alpha and ferritin may contribute to the insulin resistance found in HCV positive Egyptian patients. Current Medical Research and Opinion. 2005;21:527–534
  20. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R, et al. Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis. Lancet. 1992;340:548
  21. Fabris P, Betterle C, Greggio NA, Zanchetta R, Bosi E, Biasin MR, et al. Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis. Journal of Hepatology. 1998;28:514–517
  22. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care. 1999;22:1978–1983
  23. Fraser GM, Harman I, Meller N, Niv Y, Porath A. Diabetes mellitus is associated with chronic hepatitis C but not chronic hepatitis B infection. Israel Journal of Medical Sciences. 1996;32:526–530
  24. Fukui M, Kitagawa Y, Nakamura N, Yoshikawa T. Hepatitis C virus and atherosclerosis in patients with type 2 diabetes. Journal of the American Medical Association. 2003;289:1245–1246
  25. Gray H, Wreghitt T, Stratton IM, Alexander GJ, Turner RC, O'Rahilly S. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal liver function tests. Diabetic Medicine. 1995;12:244–249
  26. Greenberg AS, McDaniel ML. Identifying the links between obesity, insulin resistance and beta-cell function: Potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes. European Journal of Clinical Investigation. 2002;32(Suppl. 3):24–34
  27. Grimbert S, Valensi P, Levy-Marchal C, Perret G, Richardet JP, Raffoux C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterologie Clinique et Biologique. 1996;20:544–548
  28. Guerci AP, Guerci B, Levy-Marchal C, Ongagna J, Ziegler O, Candiloros H, et al. Onset of insulin-dependent diabetes mellitus after interferon-alfa therapy for hairy cell leukaemia. Lancet. 1994;343:1167–1168
  29. Haap M, Fritsche A, Mensing HJ, Haring HU, Stumvoll M. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Annals of Internal Medicine. 2003;139:869–871
  30. Hadziyannis S, Karamanos B. Diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:604–605
  31. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: Implications for therapy. Journal of Hepatology. 2003;39:1042–1048
  32. Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994;94:1543–1549
  33. Hu KQ, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, et al. Overweight and obesity, hepatic steatosis, and progression of chronic hepatitis C: A retrospective study on a large cohort of patients in the United States. Journal of Hepatology. 2004;40:147–154
  34. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125:1695–1704
  35. Hussain MJ, Lau JY, Williams R, Vergani D. Hepatic expression of tumour necrosis factor-alpha in chronic hepatitis B virus infection. J Clin Pathol. 1994;47:1112–1115
  36. Imano E, Kanda T, Ishigami Y, Kubota M, Ikeda M, Matsuhisa M, et al. Interferon induces insulin resistance in patients with chronic active hepatitis C. Journal of Hepatology. 1998;28:189–193
  37. Itoh Y, Okanoue T, Ohnishi N, Sakamoto M, Nishioji K, Nakagawa Y, et al. Serum levels of soluble tumor necrosis factor receptors and effects of interferon therapy in patients with chronic hepatitis C virus infection. American Journal of Gastroenterology. 1999;94:1332–1340
  38. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003;3:178–185
  39. Kaye TB, Guay AT, Simonson DC. Non-insulin-dependent diabetes mellitus and elevated serum ferritin level. J Diabetes Complications. 1993;7:246–249
  40. Khalili M, Lim JW, Bass N, Ascher NL, Roberts JP, Terrault NA. New onset diabetes mellitus after liver transplantation: The critical role of hepatitis C infection. Liver Transpl. 2004;10:349–355
  41. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF, et al. Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. J Clin Invest. 2000;105:199–205
  42. Knobler H, Schattner A. TNF-α, chronic hepatitis C and diabetes: A novel triad. QJM. 2005;98:1–6
  43. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75:355–359
  44. Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol. 1998;26:30–33
  45. Konrad T, Zeuzem S, Toffolo G, Vicini P, Teuber G, Briem D, et al. Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion. 2000;62:52–59
  46. Konrad T, Zeuzem S, Vicini P, Toffolo G, Briem D, Lormann J, et al. Evaluation of factors controlling glucose tolerance in patients with HCV infection before and after 4 months therapy with interferon-alpha. European Journal of Clinical Investigation. 2000;30:111–121
  47. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology. 1992;130:43–52
  48. Laskus T, Radkowski M, Wang LF, Vargas H, Rakela J. Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: Specific detection of negative-strand viral RNA in various tissues. Hepatology. 1998;28:1398–1401
  49. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Garcia L, et al. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diabetes Care. 2004;27:2669–2675
  50. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Simo R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care. 2004;27:1171–1175
  51. Lerat H, Honda M, Beard MR, Loesch K, Sun J, Yang Y, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology. 2002;122:352–365
  52. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: Mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586–597
  53. Lopes EP, Oliveira PM, Silva AE, Ferraz ML, Costa CH, Miranda W, et al. Exacerbation of type 2 diabetes mellitus during interferon-alfa therapy for chronic hepatitis B. Lancet. 1994;343:244
  54. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clinic Proceedings. 1980;55:434–438
  55. Maeno T, Okumura A, Ishikawa T, Kato K, Sakakibara F, Sato K, et al. Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection. J Gastroenterol Hepatol. 2003;18:1358–1363
  56. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease: A feature of the metabolic syndrome. Diabetes. 2001;50:1844–1850
  57. Marinos G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–923
  58. Marinos G, Naoumov NV, Rossol S, Torre F, Wong PY, Gallati H, et al. Tumor necrosis factor receptors in patients with chronic hepatitis B virus infection. Gastroenterology. 1995;108:1453–1463
  59. Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005;28:940–941
  60. Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328–333
  61. Mayo MJ. Extrahepatic manifestations of hepatitis C infection. The American Journal of the Medical Sciences. 2002;325:135–148
  62. Mehta SH, Brancati FL, Strathdee SA, Pankow JS, Netski D, Coresh J, et al. Hepatitis C virus infection and incident type 2 diabetes. Hepatology. 2003;38:50–56
  63. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Annals of Internal Medicine. 2000;133:592–599
  64. Mora PF. Post-transplantation diabetes mellitus. Am J Med Sci. 2005;329:86–94
  65. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78(Pt 7):1527–1531
  66. Ozyilkan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. American Journal of Gastroenterology. 1996;91:1480–1481
  67. Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, et al. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: Further evidence for an etiologic association. Hepatology. 2002;35:367–372
  68. Paz K, Hemi R, LeRoith D, Karasik A, Elhanany E, Kanety H, et al. A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtamembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation. Journal of Biological Chemistry. 1997;272:29911–29918
  69. Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, et al. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. Journal of Hepatology. 2001;35:279–283
  70. Piquer S, Hernandez C, Enriquez J, Ross A, Esteban JI, Genesca J, et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon. J Lab Clin Med. 2001;137:38–42
  71. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75–85
  72. Previs SF, Withers DJ, Ren JM, White MF, Shulman GI. Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism in vivo. Journal of Biological Chemistry. 2000;275:38990–38994
  73. Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T. Fibrogenic impact of high serum glucose in chronic hepatitis C. Journal of Hepatology. 2003;39:1049–1055
  74. Ruan H, Hacoben N, Golub TR, Van Parijs L, Lodish HF. Tumor necrosis factor-alpha suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: Nuclear factor-kappaB activation by TNF-alpha is obligatory. Diabetes. 2002;51:1319–1336
  75. Ruan H, Lodish HF. Insulin resistance in adipose tissue: Direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev. 2003;14:447–455
  76. Salmela PI, Sotaniemi EA, Niemi M, Maentausta O. Liver function tests in diabetic patients. Diabetes Care. 1984;7:248–254
  77. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz ML, et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. American Journal of Gastroenterology. 2003;98:2064–2071
  78. Shiba T, Morino Y, Tagawa K, Fujino H, Unuma T. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract. 1995;30:237–241
  79. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: Direct involvement of the virus in the development of insulin resistance. Gastroenterology. 2004;126:840–848
  80. Simo R, Hernandez C, Genesca J, Jardi R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care. 1996;19:998–1000
  81. Tanaka H, Shiota G, Kawasaki H. Changes in glucose tolerance after interferon-alpha therapy in patients with chronic hepatitis C. J Med. 1997;28:335–346
  82. Waguri M, Hanafusa T, Itoh N, Imagawa A, Miyagawa J, Kawata S, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract. 1994;23:33–36
  83. Woodward RS, Schnitzler MA, Baty J, Lowell JA, Lopez-Rocafort L, Haider S, et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant. 2003;3:590–598
  84. Yamauchi T, Tobe K, Tamemoto H, Ueki K, Kaburagi Y, Yamamoto-Honda R, et al. Insulin signalling and insulin actions in the muscles and livers of insulin-resistant, insulin receptor substrate 1-deficient mice. Mol Cell Biol. 1996;16:3074–3084
  85. Zein CO, Levy C, Basu A, Zein NN. Chronic hepatitis C and type II diabetes mellitus: A prospective cross-sectional study. American Journal of Gastroenterology. 2005;100:48–55
  86. Zylberberg H, Rimaniol AC, Pol S, Masson A, De Groote D, Berthelot P, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: A correlation with histological fibrosis and activity. Journal of Hepatology. 1999;30:185–191

PII: S1056-8727(06)00005-5

doi: 10.1016/j.jdiacomp.2006.01.001

Journal of Diabetes and Its Complications
Volume 20, Issue 2 , Pages 113-120 , March 2006

Article Tools

* Image Usage & Resolution